Board approves merger following independent valuation; SKNY to contribute $5M in cash or assets at closing
Mira Pharmaceuticals (MIRA), a clinical-stage company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, has announced that its Board of Directors has unanimously approved the acquisition of SKNY Pharmaceuticals, Inc. The deal follows independent valuations of both companies and sets a combined enterprise value exceeding $60 million.
The strategic merger includes a $5 million contribution from SKNY to Mira in either cash or other assets, which will be transferred at closing. A filing with the U.S. Securities and Exchange Commission is underway to obtain shareholder approval.
According to independent analysis by Moore Financial Consulting, SKNY Pharmaceuticals was assigned an enterprise value of $30.5 million, based on the risk-adjusted net present value (rNPV) of its lead compound, SKNY-1. Mira itself was valued at $30 million, creating a solid foundation for a unified company with complementary pipelines and commercial potential.
“This merger brings together two pipelines, two market opportunities, and one unified strategy,” said Erez Aminov, CEO of Mira. “Our focus remains on developing first-in-class therapies that target critical and underserved health needs.”
The centerpiece of SKNY’s pipeline is SKNY-1, an investigational oral compound that modulates cannabinoid receptors CB1 and CB2, as well as monoamine oxidase B (MAO-B)—an enzyme linked to dopamine metabolism and addiction. The compound is being developed for both obesity and nicotine dependence, two global health challenges with limited treatment options.
Industry projections underscore the market potential:
- The global weight loss drug market is expected to surpass $150 billion by 2030, with increasing demand for alternatives to injectable GLP-1 therapies (Reuters).
- The U.S. smoking cessation market is forecast to grow from $28.11 billion in 2024 to $50.90 billion by 2030, at a CAGR of 10.4% (Grand View Research).
Dr. Angel, Mira’s Chief Scientific Advisor, emphasized the scientific rationale behind SKNY-1: “This is a uniquely designed molecule that addresses the biological complexity of both obesity and addiction. The early data are promising.”
Mira views the acquisition as a pivotal step toward building a scaled, innovation-driven platform focused on areas of urgent unmet need—backed by differentiated science and a clear commercial strategy.
You might like this article:Trump Crypto Advisor David Bailey Raises $300M for New Public Bitcoin Investment Firm
